Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. This deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
According to the company, the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows, and other automation applications. Nightfood views healthcare, life sciences, and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service (RaaS) platform.
This milestone is important for the industry as it demonstrates the cross-sector potential of AI-driven robotics. For business leaders, the expansion into pharmaceutical automation signals a growing trend where robotics platforms originally designed for hospitality can be adapted to highly regulated environments like labs, potentially reducing costs, improving accuracy, and accelerating drug development processes. The collaboration between TechForce and Oncotelic could pave the way for more efficient laboratory workflows, addressing labor shortages and the need for precision in repetitive tasks.
TechForce Robotics, a subsidiary of Nightfood Holdings, develops and deploys autonomous robotic systems aimed at improving operational efficiency, workflow consistency, and scalability across various industries. The company operates through a vertically integrated platform combining proprietary robotics technology, real-world operating environments, and scalable manufacturing, delivering its solutions through a RaaS model. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications.
The successful deployment of LIM-E provides a proof of concept for the integration of autonomous robots in pharmaceutical labs, which could lead to broader adoption across the life sciences sector. For investors, this development may signal Nightfood Holdings’ potential to capture value in the growing market for laboratory automation, projected to expand as drug development becomes more complex and data-intensive. The collaboration also highlights the strategic importance of partnerships between robotics firms and biopharma companies to drive innovation.
For more information, visit Nightfood Holdings, Oncotelic Therapeutics, and TechForce Robotics. The full press release is available at https://ibn.fm/RFkfL.
